Trial
NCT02222207
Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
—
Condition
Macular Degeneration
Intervention
Regorafenib, ophthalmic oily suspension (BAY73-4506)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-09-08